PABAF (Patrys) Common Stock: $58.48 Mil (As of Dec. 2025)


What is Patrys Common Stock?

Patrys PABAF Common Stock is $58.48 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Patrys's quarterly common stock increased from Dec. 2024 ($54.30 Mil) to Jun. 2025 ($56.00 Mil) and increased from Jun. 2025 ($56.00 Mil) to Dec. 2025 ($58.48 Mil).

Patrys's annual common stock declined from Jun. 2023 ($57.54 Mil) to Jun. 2024 ($56.93 Mil) and declined from Jun. 2024 ($56.93 Mil) to Jun. 2025 ($56.00 Mil).

Patrys Common Stock Historical Data

* Premium members only.

The historical data trend for Patrys's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Patrys Common Stock Chart

Patrys Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 59.72 60.24 57.54 56.93 56.00

Patrys Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.39 56.93 54.30 56.00 58.48

Patrys Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $58.48 Mil mean?
Patrys (PABAF) has a Common Stock of $58.48 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Patrys and its competitors.
Is Patrys' Common Stock too high?
Patrys' current Common Stock is $58.48 Mil.
How does Patrys' Common Stock compare to VRTX and REGN?
Patrys' Common Stock of $58.48 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Patrys and its competitors. Patrys's current Common Stock is $58.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Patrys stock overvalued right now?
Patrys (PABAF) has a current Common Stock of $58.48 Mil. The current Common Stock is $58.48 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Patrys (PABAF), the current Common Stock is $58.48 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Patrys Business Description

Other Exchanges PABDA:Australia
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3000
Patrys Ltd is a biopharmaceutical company focused on developing novel antibody-based therapies prominently for cancer and related inflammatory diseases. Its core technology platform involves antibodies that penetrate cell nuclei and inhibit cancer cell DNA repair mechanisms. The company advances therapeutic candidates from its antibody platforms, including ones licensed from Yale University, with ongoing preclinical and clinical development activities. Patrys generates revenue through licensing agreements and collaborations linked to its antibody technologies. Its operations and development efforts span Australia and the United States.